Q-omics provides the consensus-scored LYPLA2P1 profile across patient tissues and cancer cell-line models. LYPLA2P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LYPLA2P1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, LYPLA2P1 RNA expression shows 13,465 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where LYPLA2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYPLA2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYPLA2P1 survival associations across molecular data types. LYPLA2P1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYPLA2P1 RNA expression–survival associations across cancer types. High LYPLA2P1 expression shows unfavorable associations in ACC, LUAD, LIHC, SARC and OV, but favorable associations in THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for LYPLA2P1 RNA expression.
This table summarizes LYPLA2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LYPLA2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYPLA2P1 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, HNSC, UCEC and BLCA. The LUAD box plot shows higher LYPLA2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.301, t-test p < 0.001).
This table shows molecular features associated with LYPLA2P1 in patient tissues and cancer cell lines. In patient samples, LYPLA2P1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
